Section 4 of 6
Clinical evidence
288 evidence topics · 46 sources
Study summaries
upLIFT
Objective
Objectives stated in the ClinicalTrials.gov brief summary
Main objective in the EU Clinical Trials Information System record
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2025-04-16” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2027-09” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-09” (opens the source at this quote in a new tab)
“First Posted 2025-03-18” (opens the source at this quote in a new tab)
“Last Update Posted 2026-09-28” (opens the source at this quote in a new tab)
“Recruiting” (opens the source at this quote in a new tab)
“No Results Posted” (opens the source at this quote in a new tab)
Planned number of sites and countries in the ClinicalTrials.gov record
Study locations by country in the ClinicalTrials.gov record
European member states, trial dates, and recruitment status in the EU Clinical Trials Information System record
“Locations France, Netherlands” (opens the source at this quote in a new tab)
“Start of trial 10/03/2026” (opens the source at this quote in a new tab)
“Ongoing, recruitment ended” (opens the source at this quote in a new tab)
“Estimated end of trial date in EU/EEA: 09/09/2030” (opens the source at this quote in a new tab)
“Estimated global end date of the trial: 10/09/2030” (opens the source at this quote in a new tab)
Planned conduct primarily in the United States at IND clearance
Enrollment in the United States and Europe at fiscal year end 2026
Completion of enrollment and expected topline timing
Study initiation and current status in the quarterly report
Study design
Official title in the ClinicalTrials.gov record
Allocation, intervention model, and masking in the ClinicalTrials.gov record
Study periods in the ClinicalTrials.gov record
Current single-arm, open-label design described by the company
Multicenter design in the corporate presentation
Original randomized, placebo-controlled design at IND clearance
Design change agreed with the FDA in August 2025
Removal of the hypoglycemia event endpoint in the annual report
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Age and sex eligibility in the ClinicalTrials.gov record
Requirement for continuous parenteral dextrose described by the company
Treatment
Arm and intervention in the ClinicalTrials.gov record
Pivotal dosing and extension dosing frequency
Dosing described in the results release
Once-weekly administration in the corporate presentation
Study outcomes
Rationale for using glucose infusion rate reduction of at least 50% as the primary endpoint
Primary and secondary outcome measures in the ClinicalTrials.gov record
Primary endpoint and additional endpoints defined by the company
Responder window within the pivotal treatment phase
Functional status among additional endpoints in the corporate presentation
Glucose infusion rate as an objective endpoint measured in hospital
Expanded access data that informed the endpoint and the design revision
Basis for the streamlined design stated by the company
Design modification to improve the likelihood of demonstrating efficacy
Glucose infusion rate assessment contrasted with self-monitored measures in sunRIZE
Clinical relevance of parenteral glucose dependence in tumor hyperinsulinism (insulinoma)
“Supportive strategies such as frequent carbohydrate intake or continuous parenteral dextrose infusion are often required but are burdensome and do not provide durable control, and parenteral infusions may prevent hospital discharge.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Assessments of efficacy focused on changes in GIR (since most participants initially required parenteral dextrose to correct refractory hypoglycemia) and also included assessments of hypoglycemia by CGM (described below), number of hospitalization days in the month before and after ersodetug initiation, and overall survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most individuals were receiving parenteral dextrose during baseline, which by intent likely ameliorated hypoglycemia, thus masking the severity of baseline glycemic measures by CGM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Success threshold of a lower 95% confidence bound above 30%
Agreement with the FDA on an adequate and well-controlled program
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment of 16 participants at study completion of enrollment
Participants included in the preliminary primary endpoint evaluation
Criterion for statistical significance of the responder proportion
Responder rate and confidence interval required for 16 participants
Description of analysis sets
Classification of the participant who entered hospice as a non-responder
Denominator of 16 enrolled participants for the significance threshold
Final statistical analysis pending after the preliminary evaluation
Results
Participant disposition
Preliminary disposition at the November 2026 data evaluation
Withdrawal of the participant with stage 4 colon cancer at the interim update
Continuation into the open-label extension at the interim update
Baseline characteristics
Tumor types of the 16 enrolled participants (insulinoma and non-islet cell tumor)
Mechanism of hypoglycemia in the enrolled participants
Tumor types of the first 8 participants at the interim update
Efficacy results
Preliminary primary endpoint result at the November 2026 data evaluation
Preliminary results subject to change before the final analysis
Preliminary interim result in the first 8 participants (June 2026)
Preliminary update of the first 8 participants to 7 responders
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Preliminary safety in the pivotal and extension phases (November 2026)
Preliminary drug-related adverse events stated in the prospectus supplement
Death due to cancer progression after withdrawal to hospice
Study limitations
Summary
- Design: upLIFT is a single-arm, open-label trial of 16 participants with no concurrent comparator, so the responder proportion is judged against a prespecified threshold (lower bound of the 95% confidence interval above 30%). The source documents word the threshold as “must exceed 30%” and as “must be ≥30%”.
- Status of the data: the results are preliminary and come from company press releases and SEC filings; no publication, congress presentation, or registry results exist. At the 13 November 2026 evaluation, 3 participants remained in the pivotal period, and the final responder proportion and its confidence interval may differ.
- Applicability: participants are adults who require IV glucose or parenteral nutrition despite standard-of-care therapies, with the primary endpoint measured in a hospital setting, and receive ersodetug as an add-on; the results describe the most severe presentation. Results by tumor type (insulinoma or non-islet cell tumor) and patient-reported quality of life have not been reported.
- One participant with stage 4 metastatic colon cancer withdrew to hospice and was counted as a non-responder; outcomes in participants with poor performance status are therefore represented by a single case.
- Registry records lag the company: ClinicalTrials.gov still lists the trial as recruiting, while the company reports enrollment complete.
Expanded access program in Tumor hyperinsulinism
Objective
Objective of the peer-reviewed case series: insulinoma and cervical neuroendocrine carcinoma
“We retrospectively report outcomes from compassionate use of ersodetug in 8 individuals with refractory hypoglycemia due to tumor HI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“this case series retrospectively reports on the experience of 8 individuals with refractory hypoglycemia due to tumor HI (metastatic insulin-producing tumors) who were treated with ersodetug on a compassionate use basis via an expanded access program (EAP).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Objective of the ENDO 2026 case series poster
Objective of the single published case: metastatic insulinoma
“We report the successful use of RZ358, a novel human anti–insulin receptor monoclonal antibody, in a patient with metastatic insulinoma in whom severe, refractory hypoglycemia developed after peptide receptor radionuclide therapy with lutetium Lu 177 dotatate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Purpose of the intermediate-size cohort expanded access program: insulinoma and NICTH
Location and study date
Enrollment period, data cutoff, and countries in the peer-reviewed case series
“Eight individuals with refractory hypoglycemia secondary to HI whose glycemic needs were not adequately managed by standard-of-care therapies were enrolled in the EAP beginning in November 2022; data were collected until the data cutoff of August 2025.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“were enrolled in the EAP in the United States (n = 7) and the Netherlands (n = 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First patient treated at a single U.S. center under FDA emergency use authorization
“We obtained emergency use authorization from the Food and Drug Administration, approval from the institutional review board of Beth Israel Deaconess Medical Center, and written informed consent from the patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Investigators in the United States and Europe, as stated by the company in January 2026
Status, dates, and location of the intermediate-size cohort expanded access program
| Field | Quoted record |
|---|---|
| Expanded access status | “Available” |
| Other study ID number | “RZ358-303” |
| First submitted | “2025-11-21” |
| First posted | “2025-12-04” |
| Last update posted | “2026-10-07” |
| Location | “New Orleans, Louisiana, United States, 70112” |
Program continuing after completion of upLIFT enrollment
Study design
Retrospective case series of single-patient compassionate use requests
“Enrollment was initiated by a treating physician through a named patient request (single-patient investigational new drug application) to the country health authority and was approved by local institutional review board, if required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Written informed consent was obtained from all individuals before treatment initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Change from an earlier compassionate use framework to a tumor HI-specific framework
“The first 2 individuals were enrolled under an earlier compassionate-use program framework; a subsequent, tumor HI–specific framework was implemented during the course of the third patient's treatment and applied to all remaining individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The updated framework incorporated a higher weekly dose that had shown superior effectiveness in early experience” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overlap of the first patient with the published single case
“For Patient 1, the continuous glucose monitoring (CGM) and glucose infusion rate (GIR) data for the 90-day pre- and post-treatment windows presented herein also were previously reported in a single case report” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“all other efficacy data for this patient are new.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This patient was the first to receive ersodetug for tumor HI, with detailed results previously reported in a case report” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Role of the expanded access data in Breakthrough Therapy Designation and the upLIFT redesign
Design of the intermediate-size cohort expanded access program
| Field | Quoted record |
|---|---|
| Official title | “Intermediate-Size Cohort EAP for Ersodetug in Patients With Refractory Hypoglycemia Due to Tumor-Associated Hyperinsulinism (Tumor HI) Who Are Unable to Participate in a Clinical Trial” |
| Study type | “Expanded Access” |
| Expanded access type | “Intermediate-size Population” |
| Condition | “Tumor-associated Hyperinsulinism (Tumor HI)” |
| Sponsor | “Rezolute” |
Eligibility criteria
Eligibility in the peer-reviewed case series
“Individuals were eligible regardless of tumor type, prior therapies, or comorbidities, provided they were clinically stable for infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All listed diagnoses were confirmed by relevant laboratory, imaging and pathology over the treatment courses and prior to initiating ersodetug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inclusion criteria of the intermediate-size cohort expanded access program: insulinoma and NICTH
Exclusion criteria of the intermediate-size cohort expanded access program
Age and sex eligibility of the intermediate-size cohort expanded access program
| Field | Quoted record |
|---|---|
| Ages eligible | “18 Years and older” |
| Sexes eligible | “All” |
Treatment
Dose, route, and schedule in the peer-reviewed case series
“Ersodetug was administered intravenously over 30 minutes at an initial dose of 6 or 9 mg/kg, given either weekly or every other week initially, followed by a frequency of every 2-5 weeks, as appropriate, at the discretion of the treating physician.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose adjustments, including titration and changes in dosing frequency, were made based on glycemic response, tolerability, and clinical course.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After exploratory dose-ranging in the first 2 participants, the initiation dose regimen was standardized in subsequent participants to 9 mg/kg weekly, followed by de-escalation as indicated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant required escalation from 9 to 12 mg/kg every other week.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concomitant standard-of-care and tumor-directed therapy
“Supportive therapies, including use of ongoing standard-of-care antihypoglycemic treatments, were noted and recorded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals resumed tumor-directed therapies or procedures as deemed appropriate by the multidisciplinary clinical care team, and these interventions were systematically recorded as part of the observational dataset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Drug supplied at no cost by the manufacturer
Dose regimen by patient in the company table of 9 patients
| Patient | Ersodetug dose regimen (dose/frequency) |
|---|---|
| Patient 1 | “6-9 mg/kg every 1-4 weeks” |
| Patient 2 | “6-9 mg/kg every 1-2 weeks” |
| Patient 3 | “9 mg/kg, every 1-2 weeks” |
| Patient 4 | “9-12 mg/kg every 1-2 weeks” |
| Patient 5 | “9 mg/kg every 1-3 weeks” |
| Patient 6 | “9 mg/kg every 1-2 weeks” |
| Patient 7 | “6-9 mg/kg every 1-2 weeks” |
| Patient 8 | “9 mg/kg every 1-2 weeks” |
| Patient 9 | “9 mg/kg every 1-3 weeks” |
Dosing in the ENDO 2026 case series poster
Intervention in the intermediate-size cohort expanded access program
| Field | Quoted record |
|---|---|
| Intervention | “Drug: Ersodetug (9 mg/kg) + SOC” |
| Description | “Open-Label Participants with a diagnosis of Tumor HI (insulin- or IGF-producing tumors)” |
Study outcomes
Rationale for using discontinuation of parenteral glucose as the primary outcome
No prespecified primary outcome: efficacy assessments centered on glucose infusion rate
“Assessments of efficacy focused on changes in GIR (since most participants initially required parenteral dextrose to correct refractory hypoglycemia) and also included assessments of hypoglycemia by CGM (described below), number of hospitalization days in the month before and after ersodetug initiation, and overall survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eastern Cooperative Oncology Group (ECOG) performance status was used to assess functional ability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ersodetug dosing regimen, treatment duration, and safety observations (serious adverse events and drug-related serious adverse events) were also recorded and assessed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Parenteral dextrose at baseline masks hypoglycemia measured by continuous glucose monitoring
“Most individuals were receiving parenteral dextrose during baseline, which by intent likely ameliorated hypoglycemia, thus masking the severity of baseline glycemic measures by CGM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, changes from baseline in CGM should be interpreted accordingly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Continuous glucose monitoring outcomes and windows
“CGM data were analyzed for mean sensor glucose and percent of time in predefined glycemic ranges (eg, <70 mg/dL, <54 mg/dL, and >180 mg/dL).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline for CGM purposes was defined as the period up to 90 days before the first dose of ersodetug, and the evaluable window was defined as the period up to 90 days after initiation; longer follow-up CGM data were included in a sensitivity analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Its pharmacokinetic characteristics informed selection of a 90-day evaluable window during which drug concentrations were expected to be at steady-state for most individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Parenteral infusion as a barrier to discharge and to tumor-directed therapy
“Supportive strategies such as frequent carbohydrate intake or continuous parenteral dextrose infusion are often required but are burdensome and do not provide durable control, and parenteral infusions may prevent hospital discharge.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These functional gains enabled most individuals to pursue tumor-directed therapies, including chemotherapy, surgery, and hepatic arterial embolization, underscoring the importance of glycemic stabilization as a prerequisite for oncologic care in this population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucose infusion rate as the focus of the ENDO 2026 case series analysis
Glucose infusion rate assessment shared with the upLIFT primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Peer-reviewed case series: 8 participants
“Eight adults (4M/4F; 24-74 years; Eastern Cooperative Oncology Group [ECOG] 1-3) received ersodetug for insulin-secreting tumors (metastatic insulinoma, n = 7; cervical neuroendocrine carcinoma, n = 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All 8 individuals had CGM data available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company table filed with the SEC: 9 patients
ENDO 2026 company release: 9 patients with malignant insulinoma and non-islet cell tumors
Total patients treated under the program, as stated by the company: more than 10 to 13
Description of analysis sets
Analysis population and evaluation periods in the peer-reviewed case series
“In this retrospective analysis, observational data were collected until August 2025 (or earlier treatment discontinuation) in all individuals who received at least one infusion of ersodetug and had available follow-up data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For standardization of glycemic assessments, baseline was defined as the period up to 90 days prior to ersodetug initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The evaluable period was defined as the time from ersodetug initiation until the data cutoff (August 2025) or treatment discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Parenteral glucose subset: 7 of 8 participants
Paired nonparametric comparisons without formal hypothesis testing
“Changes in percent time in glycemic ranges and medication counts were assessed from paired comparisons of the baseline period (up to 90 days) with the post-initiation evaluable period (up to 90 days) using the Wilcoxon-signed rank test in R.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“95% intervals could not be constructed due to the sample size [N = 8] and discrete nature of the test” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Strength of statistical evidence was evaluated using nominal P-values, but no formal or prespecified hypothesis testing was conducted due to the retrospective nature of the report and limited sample size.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A statistical analysis plan with additional details of the statistical methods was developed after primary data analyses and is available in the Supplemental Appendix” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Treatment duration, dosing de-escalation, and deaths in the peer-reviewed case series
“Most individuals (n = 6/8) were able to decrease the dosing frequency of ersodetug after hospital discharge.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median treatment duration with ersodetug of 11.5 months (range 5-17 months; ongoing in 2 individuals) also corresponded to patient lifespan and overall survival in the setting of metastatic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the individuals who died (n = 6), tumor progression and sepsis were cited as the cause, unrelated to the investigational drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment duration and survival by patient in the company table of 9 patients
| Patient | Total duration of ersodetug therapy (months) | Overall survival (months) |
|---|---|---|
| Patient 1 | “13” | “14” |
| Patient 2 | “5” | “5” |
| Patient 3 | “5” | “5” |
| Patient 4 | “14” | “14” |
| Patient 5 | “22 (ongoing)” | “22 (living)” |
| Patient 6 | “18 (ongoing)” | “18 (living)” |
| Patient 7 | “6” | “6” |
| Patient 8 | “1.5” | “1.5” |
| Patient 9 | “10” | “10” |
Critically ill patient who died of sepsis before response could be assessed: company table
First two patients still receiving treatment in October 2023
Baseline characteristics
Demographics and clinical characteristics in the peer-reviewed case series
“All individuals were White; 7 identified as non-Hispanic and one as Hispanic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seven individuals had metastatic insulinoma and one had neuroendocrine carcinoma of the cervix.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cohort was characterized by predominantly metastatic disease with substantial hepatic involvement and variable but often abnormal liver biochemistry, along with renal function ranging from normal to mildly impaired at the time of ersodetug initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalization at entry stated in the text of the peer-reviewed case series
Prior therapy, home parenteral nutrition, performance status, and hospice consideration at entry
“All individuals had received and were refractory to at least 3 standard-of-care therapies, including diazoxide, short- and long-acting somatostatin analogs, everolimus, and/or corticosteroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two individuals initiated ersodetug prior to hospitalization, including one receiving continuous carbohydrate supplementation via home TPN.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Four of the 8 individuals had a baseline ECOG score of 3, 1 had an ECOG of 2, and 3 had an ECOG of 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two individuals were under hospice consideration at baseline due to refractory hypoglycemia, progressive disease, and lack of remaining tumor-directed treatment options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Demographics, tumor, and organ function by patient in the peer-reviewed case series
Hospitalization, performance status, and prior antihypoglycemic therapy by patient in the peer-reviewed case series
Baseline characteristics by patient in the company table of 9 patients
| Characteristic | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 |
|---|---|---|---|---|---|---|---|---|---|
| Gender (M/F) / age (years) | “M / 55” | “F / 50” | “F / 50” | “F / 43” | “M / 74” | “M / 62” | “M / 74” | “M / 53” | “M / 24” |
| Diagnosis | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Neuroendocrine Carcinoma of the Cervix” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Proinsulinoma” | “Metastatic Insulinoma” |
| Number of antihypoglycemic therapies at enrollment | “4” | “3” | “3” | “4” | “4” | “3” | “5” | “2” | “4” |
| GIR at ersodetug initiation (mg/kg/min) | “6.0” | “7.0 (home TPN)” | “5.1” | “6.2” | “4.9” | “n/a (ambulatory)” | “5.6” | “Unknown amount” | “3.1” |
| Length of hospitalization before ersodetug (days) | “28” | “n/a (ambulatory)” | “15” | “49” | “34” | “n/a (ambulatory)” | “4” | “Unknown duration” | “16” |
| Baseline ECOG | “3” | “2” | “3” | “3” | “3” | “1” | “1” | “3” | “1” |
Patients and tumor types in the NANETS 2024 poster
| Patient | Gender | Age | Tumor type |
|---|---|---|---|
| Patient 1 | “M” | “55” | “Metastatic Insulinoma” |
| Patient 2 | “F” | “50” | “Metastatic Insulinoma” |
| Patient 3 | “F” | “50” | “Metastatic Insulin-Secreting Tumor (Cervical Primary)” |
| Patient 4 | “F” | “43” | “Metastatic Insulinoma” |
| Patient 5 | “M” | “74” | “Metastatic Insulinoma” |
Parenteral dextrose and hospital setting at entry in the NANETS 2024 poster
Single published case: presentation, tumor, and biochemistry
“A 55-year-old man presented with a 5-month history of abdominal pain and weight loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A liver biopsy revealed a pancreatic neuroendocrine tumor” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“with a pathogenic MEN1 mutation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hormonal analysis, performed when the venous glucose level was 41 mg per deciliter (2.3 mmol per liter), revealed inappropriately high levels of insulin, at 45 μIU per milliliter (312 pmol per liter; reference value, <19.6 μIU per milliliter [141 pmol per liter]); C-peptide, at 6.5 ng per milliliter (reference range, 0.80 to 3.85); and proinsulin, at 453 pmol per liter (reference value, <18).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single published case: refractory hypoglycemia on maximal therapy before ersodetug
“Intravenous 50% dextrose solution was infused through a central line, at a rate of up to 60 ml (30 g) per hour, which reflects very high glucose use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite enteral nutrition support and treatment with high-dose diazoxide, everolimus, dexamethasone, pasireotide, and glucagon, the patient remained hypoglycemic, with up to 58% of all sensor glucose values in each 24-hour period being less than 70 mg per deciliter [3.9 mmol per liter] and up to 19% being less than 54 mg per deciliter (3.0 mmol per liter)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Summary of glycemic outcomes in the peer-reviewed case series
“Most patients experienced improved glycemic control, including discontinuation of parenteral glucose in 6 of the 7 applicable patients (median, 4.5 days) and a 35.6% relative reduction from baseline in time in hypoglycemia (<70 mg/dL) by continuous glucose monitoring (mean 12.4-8.0%; pseudo-median paired change of -3.8 percentage points [90% CI, −8.2 to −1.1]; P = .02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Discontinuation of parenteral glucose: 6 of 7 participants
“Six of 7 individuals on parenteral glucose support at baseline discontinued it within the 90-day post-therapy window (median time, 4.5 days), which allowed for subsequent reductions in other standard-of-care antihypoglycemic therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One individual on home TPN initiated ersodetug contemporaneously with ablation of primary hepatic metastases, ultimately achieving a 50% reduction in intravenous carbohydrate support after dose escalation of ersodetug to 9 mg/kg biweekly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Number of antihypoglycemic therapies before and after initiation
Time to discontinuation of each antihypoglycemic therapy by patient (days unless stated)
Hospital discharge, tumor-directed therapy, performance status, and survival by patient
Time below 70 mg/dL, time below 54 mg/dL, and hyperglycemia by continuous glucose monitoring
“Seven of 8 individuals achieved a reduction in percent time in hypoglycemia, with a mean decrease from 12.4% at baseline to 8.0% after receiving ersodetug (35.6% relative reduction), equating to a median absolute change of −3.8% (90% CI, −8.2 to −1.1; P = .02)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Percent time in Level 2 hypoglycemia (<54 mg/dL) also trended numerically lower, with a mean decrease from 2.6% at baseline to 1.9% after receiving ersodetug (median absolute change of −0.5%; 90% CI, −2.9 to 1.3; P = .38).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reductions in overnight percent time in overall and Level 2 hypoglycemia were also observed, but statistical evidence was limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No hyperglycemia-related adverse events or need for insulin were reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Continuous glucose monitoring parameters over 24 hours, by day, and by night
Continuous glucose monitoring sensitivity analysis
“In a sensitivity analysis that incorporated all available CGM data beyond the initial 90-day windows for patients with evaluable recordings, clinical patterns remained consistent with the primary analysis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospital discharge and tumor-directed therapy after initiation
“The median time to hospital discharge after initiation of ersodetug was 9 days (range, 1-84); all patients hospitalized at baseline (n = 6) were discharged to home for treatment, including 2 who were previously considering hospice-level care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within 8 weeks of ersodetug initiation, nearly all individuals (n = 7) were able to proceed with tumor-directed therapies, including chemotherapy (n = 7), surgery (n = 4), and other medical procedures such as hepatic arterial embolization (n = 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Response by starting dose
“Glycemic stabilization was achieved across dosing regimens, with a more pronounced response observed in individuals initiated at 9 mg/kg weekly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More protracted responses to ersodetug and longer times to hospital discharge in initially treated individuals were associated with lower starting doses and less frequent administration of ersodetug (6 mg/kg and/or biweekly administration).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ENDO 2026 poster: 7 of 8 patients on parenteral glucose with at least 50% reduction
Glucose infusion rate, hospitalization, and performance status outcomes by patient in the company table of 9 patients
| Outcome | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 |
|---|---|---|---|---|---|---|---|---|---|
| Percent reduction in GIR by 8 weeks | “>50%, then 100% by 9 weeks” | “<50%” | “100%” | “100%” | “100%” | “n/a” | “100%” | “Unknown amount” | “100%” |
| Time to IV glucose discontinuation (days) | “74” | “139 (achieved 50% reduction)” | “4” | “5” | “2” | “n/a” | “3” | “n/a” | “42” |
| Hospitalized days in the 30 days after initiation | “30” | “0” | “7” | “8” | “8” | “0” | “16” | “30” | “1” |
| ECOG at month 3 | “0” | “2” | “0” | “0” | “0” | “0” | “1” | “5” | “0” |
Company summary: 75% of patients on IV dextrose or parenteral nutrition discontinued it
NANETS 2024 poster: 4 of 5 patients discontinued parenteral dextrose
Single published case: hypoglycemia, dextrose infusion, and discharge after ersodetug
“After the second RZ358 infusion (at a dose of 6 mg per kilogram of body weight), the hypoglycemia attenuated, with less than 1% of all sensor glucose values in each 24-hour period being less than 54 mg per deciliter, a result that permitted a reduction in the rate of dextrose infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After four additional infusions of RZ358 (each at a dose of 9 mg per kilogram), metabolic stability allowed discontinuation of other therapies, despite persistent excessive insulin secretion, elevated lactate dehydrogenase level” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Initiation of the anti–insulin receptor monoclonal antibody RZ358 (day 0) was successful in reducing the frequency of hypoglycemia, and the patient was able to safely receive a second dose of LU (day 67), which allowed for discharge home on day 83 after initiation of RZ358 therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The patient has remained free of severe hypoglycemia after 9 months of RZ358 therapy, currently administered at monthly intervals, with no evidence of adverse effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Second patient: insulin-secreting cervical cancer
Health-related quality of life and patient-reported outcomes
No quality of life instrument: functional benefit reported as clinician-rated performance status
“With improvements in glycemic control, all individuals experienced associated functional benefits, including hospital discharge in previously prolonged inpatient cases, and marked improvements in ECOG performance status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Resumption of daily activities, as stated by the company without a measurement instrument
Safety results
Serious adverse events and drug-related events in the peer-reviewed case series
“No drug-related serious adverse events were observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ersodetug was generally safe and well tolerated among all individuals and across all dose levels and regimens.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no drug-related deaths, adverse drug reactions, discontinuations due to adverse events, treatment-emergent clinically significant laboratory abnormalities indicative of organ toxicity, or other dose-limiting toxicities, as determined by treating physicians and reviewed by the sponsor's safety committee.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As depicted in Table 4, 3 of 8 individuals experienced serious adverse events, all attributed to underlying tumor progression or tumor-directed therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-emergent serious adverse events, pooled cohort of 8
| Measure | Pooled cohort (n = 8), number (%) |
|---|---|
| Individuals with serious TEAEs, n (%) | “3 (37.5%)”View highlighted excerpt for this quote |
| Total SAEs | “4”View highlighted excerpt for this quote |
| Individuals with PI-judged study drug-related SAEs, n (%) | “0 (0%)”View highlighted excerpt for this quote |
| Grade 1 (mild) | “1 (12.5%)”View highlighted excerpt for this quote |
| Grade 2 (moderate) | “0 (0%)”View highlighted excerpt for this quote |
| Grade 3 (severe) | “2 (25%)”View highlighted excerpt for this quote |
| Grade 4 (life-threatening) | “1 (12.5%)”View highlighted excerpt for this quote |
| Grade 5 (death) | “0 (0%)”View highlighted excerpt for this quote |
Disease progression not counted as an adverse event, and hyperglycemia
“Disease progression was not reported as a treatment-emergent adverse event, as per EAP treatment guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A corresponding increase in time above 180 mg/dL was observed, but without associated clinical impact.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ENDO 2026 poster: no drug-related serious adverse events in 9 patients
Company statement on side effects
Study limitations
Summary
- Design: the peer-reviewed report is a retrospective case series of 8 individuals treated under single-patient compassionate use, with no control group. The authors used nominal P-values without formal or prespecified hypothesis testing, could not construct 95% intervals, and developed the statistical analysis plan after the primary analyses.
- Confounding: within 8 weeks of starting ersodetug, 7 individuals received chemotherapy, 4 had surgery, and 5 had other procedures such as hepatic arterial embolization, which can also reduce hypoglycemia. Doses and schedules changed during the program, and the first 2 individuals were treated under an earlier framework at a lower weekly dose.
- Inconsistent counts and data: the number of patients differs by source (5 in the NANETS 2024 poster, 8 in the publication, 9 in the company table and ENDO 2026 poster). The company table and the publication differ in a patient's sex (“F; 74” and “M / 74”), and the publication gives hospitalization at entry as “median, 28 days; range, 4-66 days” in its text while its table lists a longest stay of 49 days. A company release describes the 9 patients as having malignant insulinoma and non-islet cell tumors, while the case-level tables list insulin-secreting tumors.
- Overlap: the first patient's glucose data were previously published as a single case report, so that case is not independent evidence.
- Safety ascertainment: disease progression was not reported as an adverse event under the program guidelines.
sunRIZE
Objective
Objective and population stated by the company
Relevance of the congenital HI trial to tumor HI stated by the company
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2024-01-11” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-11-14” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-11-14” (opens the source at this quote in a new tab)
“First Posted 2024-01-17” (opens the source at this quote in a new tab)
“Last Update Posted 2026-01-08” (opens the source at this quote in a new tab)
“Active, not recruiting” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Study locations by country in the ClinicalTrials.gov record
| Country | Locations listed in the record |
|---|---|
| United States | “Philadelphia, Pennsylvania, United States, 19104”; “Fort Worth, Texas, United States, 76104” |
| Bulgaria | “Varna, Bulgaria, 9010” |
| Denmark | “Odense, Denmark, 5000” |
| France | “Bron, France, 69677”; “Paris, France, 75015” |
| Georgia | “Tbilisi, Georgia, 0159” |
| Germany | “Berlin, Germany, 13353”; “Düsseldorf, Germany, 40225” |
| Greece | “Athens, Greece, 115 27” |
| Oman | “Seeb, Oman, 123” |
| Qatar | “Al Rayyan, Qatar” |
| Spain | “Barcelona, Spain, 08035”; “Seville, Spain, 41013” |
| Turkey (Türkiye) | “Ankara, Turkey (Türkiye), 06800” |
| United Kingdom | “London, United Kingdom, WC1N 3JH”; “Manchester, United Kingdom, M13 9WL” |
| Vietnam | “Hà Nội, Vietnam, 100000” |
Countries and U.S. enrollment stated by the company
Completion of enrollment
Announcement of topline results
Study design
Design in the ClinicalTrials.gov record
Randomization scheme and open-label infant arm in the ClinicalTrials.gov record
Treatment periods and open-label extension in the congress presentation
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Body mass index exclusion in the ClinicalTrials.gov record
Key inclusion criteria in the congress presentation
“Ages 3 months – 45 years” (opens the source at this quote in a new tab)
“Biochemically established diagnosis of cHI” (opens the source at this quote in a new tab)
“Persistent hypoglycemia despite SoC” (opens the source at this quote in a new tab)
“SMBG: >3 hypo (<70 mg/dL) per week” (opens the source at this quote in a new tab)
“CGM: >8% avg daily time <70 mg/dL” (opens the source at this quote in a new tab)
Treatment
Treatment arms in the ClinicalTrials.gov record
Dose, schedule, and background therapy stated by the company
Route and infusion duration of ersodetug
Dosing in the open-label extension
Study outcomes
Rationale for using weekly hypoglycemia events by self-monitored blood glucose as the primary endpoint
Primary outcome in the ClinicalTrials.gov record
Key secondary outcome in the ClinicalTrials.gov record
Primary and key secondary endpoints stated by the company
Other glycemic outcomes in the ClinicalTrials.gov record
Safety outcomes in the ClinicalTrials.gov record
Limitations of self-monitored blood glucose metrics acknowledged by the FDA
Unblinded self-monitored glucose as a source of bias stated by the company
Glucose monitoring as both safety tool and endpoint in an ambulatory trial
Key secondary endpoint: percent time in hypoglycemia by continuous glucose monitoring
Contrast with the inpatient glucose infusion rate endpoint of the tumor HI trial
Statistical analysis description
Number of participants (Planned and analyzed)
Planned power for the primary endpoint
Planned and actual enrollment stated by the company
Participants in the per protocol set
Description of analysis sets
Analysis window and effect measure
Pre-specified, post-hoc, and sensitivity analyses submitted to the FDA
Full analysis set
No evidence found.
Results
Participant disposition
Completion of the controlled period and entry into the open-label extension
Retention in the open-label extension, January 2026
Retention in the open-label extension, June 2026
Retention in the open-label extension, September 2026
Treatment duration in the open-label extension, November 2026
Planned conclusion of the open-label extension
Baseline characteristics
Demographics, background therapy, and baseline glycemia of the enrolled population
Preliminary baseline summary reported in November 2025
“Average age of 3.4 years (range: 3m – 15y)” (opens the source at this quote in a new tab)
“Average of 15 hypoglycemia events/week by SMBG” (opens the source at this quote in a new tab)
“40% on DZ” (opens the source at this quote in a new tab)
“67% on SSAs” (opens the source at this quote in a new tab)
“13% had previous pancreatectomy” (opens the source at this quote in a new tab)
Efficacy results
Primary endpoint: weekly hypoglycemia events by self-monitored blood glucose not met
Key secondary endpoint: percent time in hypoglycemia by continuous glucose monitoring not met
Percent time in hypoglycemia by continuous glucose monitoring at earlier time points, full analysis set
Percent time in hypoglycemia by continuous glucose monitoring, per protocol set
Pre-specified and post-hoc continuous glucose monitoring endpoints
Drug concentrations and insulin biomarker response
Preliminary open-label extension observations
FDA Type B meeting on the efficacy results, March 2026
FDA review of the submitted datasets and pre-BLA recommendation, October 2026
Timing of the pre-BLA meeting and possibility of a further randomized study
Possible effect of the sunRIZE results on the FDA assessment of the tumor HI trial
Health-related quality of life and patient-reported outcomes
Patient-reported quality of life outcomes under evaluation
Patient and family experience in the open-label extension
Safety results
Overall adverse events and adverse drug reactions
Study limitations
Summary
- Population: sunRIZE enrolled participants with congenital hyperinsulinism aged 3 months to 45 years, a different disease and a younger population than adults with tumor hyperinsulinism, so its efficacy results are indirect evidence for this report. Its main relevance here is the safety data and its effect on the regulatory assessment.
- Outcome: the trial did not meet its primary or key secondary endpoint. The favorable continuous glucose monitoring results at earlier time points and in the per protocol set are nominal, and the company's explanation of the result (self-monitored measures confounded by functional unblinding through real-time glucose monitoring) is its own interpretation.
- Reporting: results are available only from company releases, filings, and congress slides, with no peer-reviewed publication. Sources differ on the number of discontinuations for hypersensitivity (2 serious reactions in the topline release; 3 participants in the congress slides; 4 early terminations in the January 2026 presentation), on the CGM result at 10 mg/kg (“approximate 25% reduction” against “-32%; p=0.30”), and on hypertrichosis (36% and about 35%). One baseline cell reads “12 (66%)” for 12 of 20 participants. The registry still lists an estimated enrollment of 56.
- The open-label extension is ongoing, and its glycemic observations are described by the company as preliminary.
RIZE
Objective
Location and study date
Study dates in the trial registry
| Milestone | Quoted date |
|---|---|
| Study start (actual) | “2020-02-24” |
| Primary completion (actual) | “2022-04-05” |
| Study completion (actual) | “2022-08-19” |
Number of centers and countries
Study sites listed in the trial registry
Study design
Open-label, repeat-dose study in four sequential ascending-dose cohorts
Design description in the trial registry
Add-on to standard of care with unchanged diet and activity
Eligibility criteria
Congenital hyperinsulinism with persistent hypoglycemia despite standard of care
Exclusion criteria in the primary publication
Inclusion and exclusion criteria in the trial registry, including exclusion of malignancy
Treatment
Dose regimens by cohort in the trial registry
Intravenous infusion over at least 30 minutes every other week, added to standard of care
Inpatient administration and follow-up visits
Study outcomes
Rationale for using percent time in glucose target range 70-180 mg/dL by continuous glucose monitoring as the primary endpoint
Registered primary outcome measures
Primary and key secondary glycemic endpoints in the primary publication
Authors' assessment of time in range as an endpoint in congenital hyperinsulinism
Hypoglycemia events and time in hypoglycemia as the clinically relevant outcomes
Registered secondary outcome measures, including a fasting challenge
Glucose measurement devices and safety assessments
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size not powered for the glycemic endpoints
Participants analyzed in each population
Exclusions from the per-protocol glucometer analyses in the trial registry
Description of analysis sets
Safety, pharmacokinetic, and per-protocol populations
Statistical methods: Wilcoxon signed-rank test of change from baseline
Results
Participant disposition
Screened, enrolled, and completed participants
Protocol violations leading to per-protocol exclusion
Baseline characteristics
Demographics and baseline disease characteristics, intention-to-treat population
| Parameter | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 8) | Cohort 4, 3 to 9 mg/kg (n = 3) | Pooled (n = 23) |
|---|---|---|---|---|---|
| Age in years, mean (range) | “5.8 (2–12)” | “9.3 (2–22)” | “5.8 (2–17)” | “4.0 (2–6)” | “6.7 (2–22)” |
| Male, n | “4” | “5” | “3” | “1” | “13 (57%)” |
| KATP channel mutation, n | “1” | “5” | “4” | “1” | “11 (48%)” |
| Unknown genetic etiology | “3” | “2” | “3” | “1” | “9 (39%)” |
| Congenital HI therapy, n (%) | “4” | “7” | “6” | “3” | “20 (87%)” |
| Diazoxide | “2” | “3” | “1” | “2” | “8 (35%)” |
| Somatostatin analog (long acting/short acting) | “2/0” | “2/2” | “3/3” | “1/0” | “8/5 (52%)” |
| Enteral or tube use | “0” | “2” | “3” | “0” | “5 (22%)” |
| Pancreatectomy | “0” | “0” | “3” | “1” | “4 (17%)” |
| History of seizure, n | “4” | “4” | “5” | “3” | “16 (70%)” |
| Hospitalization within the past year, n | “3” | “3” | “6” | “2” | “14 (61%)” |
| Percent time in range (70–180 mg/dL) by CGM, mean (range) | “82 (74–89)” | “74 (66–89)” | “71 (12–90)” | “68 (57–87)” | “74 (12–90)” |
| Percent time in hypoglycemia (<70 mg/dL) by CGM, mean (range) | “16 (11–22)” | “22 (11–32)” | “24 (6–88)” | “29 (11–42)” | “23 (6–88)” |
| Hypoglycemia events/week (<70 mg/dL) by SMBG, mean (range) | “8 (1–13)” | “16 (4–52)” | “15 (7–29)” | “8 (4–11)” | “13 (1–52)” |
Age distribution, background therapy, and history of hospitalization and seizures
Company-reported baseline characteristics
Efficacy results
Primary endpoint: percent time in range 70-180 mg/dL by CGM, per-protocol population
| Measure | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 7) | Cohort 4, 3 to 9 mg/kg (n = 3) | Pooled (n = 22) |
|---|---|---|---|---|---|
| Median daily percent time in range at baseline | “81.7” | “72.9” | “83.4” | “59.3” | “76.9” |
| Median daily percent time in range at week 8 | “84.8” | “78.5” | “82.9” | “70.8” | “79.1” |
| Median percent change from baseline | “6.19” | “0.31” | “5.52” | “9.07” | “4.59” |
Primary endpoint: time in range not significantly changed
Key secondary endpoints: hypoglycemia events by SMBG and time in hypoglycemia by CGM, per-protocol population
| Metric | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 7) | Cohort 4, 3 to 9 mg/kg (n = 3) | Pooled, median (range) |
|---|---|---|---|---|---|
| Hypoglycemia events (<70 mg/dL) by BGM, events/week, baseline | “10.1” | “12.5” | “13.0” | “9.3” | “11.5 (4.0–52.0)” |
| Hypoglycemia events (<70 mg/dL) by BGM, events/week, end of treatment | “9.9” | “6.6” | “1.9” | “7.6” | “5.0 (0–23.8)” |
| Hypoglycemia events (<70 mg/dL), % change from baseline (p value) | “−1.6 (NS)” | “−48 (0.016)” | “−84 (0.016)” | “−19.9 (NS)” | “−59 (<0.001)” |
| Severe hypoglycemia events (<50 mg/dL), % change from baseline (p value) | “−40 (NS)” | “−78 (NS)” | “−100 (0.016)” | “−27 (NS)” | “−78 (0.005)” |
| Time in hypoglycemia (<70 mg/dL) by CGM, %, baseline | “16.3” | “20.3” | “13.7” | “34.4” | “16.2 (6–88)” |
| Time in hypoglycemia (<70 mg/dL) by CGM, %, end of treatment | “12.3” | “6.7” | “5.4” | “20.4” | “8.5 (0.3–34)” |
| Time in hypoglycemia (<70 mg/dL), % change from baseline (p value) | “−31 (NS)” | “−65 (0.023)” | “−61 (0.016)” | “−47 (NS)” | “−54 (<0.001)” |
| Time in severe hypoglycemia (<50 mg/dL), % change from baseline (p value) | “−22 (NS)” | “−74 (NS)” | “−85 (NS)” | “−61 (NS)” | “−65 (NS)” |
Key secondary endpoints: summary of reductions in hypoglycemia
Overnight hypoglycemia and time above range, per-protocol population
| Endpoint | Cohort 1, 3 mg/kg | Cohort 2, 6 mg/kg | Cohort 3, 9 mg/kg | Cohort 4, 3 to 9 mg/kg | Pooled |
|---|---|---|---|---|---|
| Overnight (8 h) percent time <70 mg/dL by CGM, % change (p value) | “−15.8 (NS)” | “−54.8 (NS)” | “−55.0 (NS)” | “−61.9 (NS)” | “−52.2 (0.006)” |
| Overnight (8 h) event rate <70 mg/dL by CGM, % change (p value) | “−15.5 (NS)” | “−49.3 (NS)” | “−42.9 (NS)” | “−56.5 (NS)” | “−40.7 (0.04)” |
| Percent time above range (>180 mg/dL) by CGM, net change | “+0.53” | “+6.7” | “+9.4” | “+10.4” | “+6.03” |
| Average overnight glucose (mg/dL) by CGM, net change | “−2.5” | “+21.5” | “+19.3” | “+19.8” | “+17.8” |
Overnight hypoglycemia: congress analysis
Pharmacokinetics and pharmacodynamics
Company-reported results for the pooled 6 and 9 mg/kg doses
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Overall safety: no deaths, adverse drug reactions, or discontinuations
Overview of treatment-emergent adverse events, safety population
| Category | Pre-treatment non-TEAE, total (n = 23) | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 8) | Cohort 4, titrate (n = 3) | Ersodetug, total (n = 23) |
|---|---|---|---|---|---|---|
| Participants with adverse events, n (%) | “10 (43)” | “2 (50)” | “7 (88)” | “5 (63)” | “2 (67)” | “16 (70)” |
| Participants with serious adverse events, n (%) | “0 (0)” | “0 (0)” | “2 (25)” | “1 (13)” | “0 (0)” | “3 (13)” |
| Participants with investigator-judged study drug-related adverse events, n (%) | “2 (9)” | “0 (0)” | “2 (25)” | “1 (13)” | “0 (0)” | “3 (13)” |
| Participants with grade 3 (severe) adverse events, n (%) | “1 (4)” | “0 (0)” | “2 (25)” | “0 (0)” | “0 (0)” | “2 (9)” |
| Participants with grade 4 (life threatening) adverse events, n (%) | “0 (0)” | “0 (0)” | “0 (0)” | “1 (13)” | “0 (0)” | “1 (4)” |
Serious adverse events
| Serious adverse event | Cohort 1, 3 mg/kg | Cohort 2, 6 mg/kg | Cohort 3, 9 mg/kg | Cohort 4, 3 to 9 mg/kg |
|---|---|---|---|---|
| “Hypoglycemia with LOC” | “0” | “1” | “0” | “0” |
| “Tonic-Clonic Seizure” | “0” | “0” | “1” | “0” |
| “Eosinophilic Leukocytosis” | “0” | “1” | “0” | “0” |
Adverse events judged related to study drug, including infusion site reactions
Company-reported exposure margin to nonclinical toxicology studies
Study limitations
Summary
- Design: RIZE was an open-label, uncontrolled study of 23 participants with sequential dose cohorts and 8 weeks of treatment, and its sample size was not powered for the primary or key secondary endpoints.
- Population: participants had congenital hyperinsulinism and were 2 years of age or older, so the study provides indirect evidence of efficacy for adults with tumor hyperinsulinism.
- Outcome: the improvements in hypoglycemia did not translate into a similar improvement in time in range, the registry primary endpoint. The registry reports this endpoint as medians in the per protocol population, while the publication reports means in the intention-to-treat population.
- Reporting: the registry results and the publication differ on sex distribution, and the 2022 company releases describe dosing as “bi-monthly” where the publication gives “every other week (bi-weekly)”.
XOMA 358 First-in-Human study
Objective
Location and study date
First participant dosed in October 2014
Study design
Double-blind, placebo-controlled, single ascending dose
Eligibility criteria
Treatment
Single intravenous infusion of placebo or 0.1 to 9 mg/kg
Study outcomes
Rationale for using safety and tolerability as the primary endpoint
Purpose of the first-in-human study: safety, pharmacokinetics, and dose selection
Pharmacodynamic endpoints: insulin tolerance test and mixed meal test
Statistical analysis description
Number of participants (Planned and analyzed)
Interim count at the March 2015 presentation
Healthy volunteer count across phase 1 studies stated in the RIZE publication
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Pharmacokinetics: dose-proportional exposure and half-life
Pharmacodynamics: insulin as a biomarker of exposure and reduced insulin sensitivity
“Dose-dependent elevations of circulating insulin levels, likely related to reduced insulin clearance via monoclonal antibody action at receptors, represented a sensitive biomarker of X358 exposure. X358-dependent increases in postprandial glucose levels and fasting homeostatic model assessment of insulin resistance values were observed and persisted for at least 1 week at the higher dose levels. In all the ITT cohorts, the slope for glucose lowering was substantially attenuated after X358 infusion of a similar magnitude, but with increasing duration with rising dose level.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Single X358 infusions were well tolerated and resulted in a dose-dependent reduction in insulin sensitivity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics at the interim presentation: postprandial glucose and insulin challenge
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No deaths, serious adverse events, or discontinuations due to adverse events
Tolerability at the interim presentation
Clinical testing limited to single-dose studies in adults after phase 1
Study limitations
Summary
- The study enrolled only healthy adult males and gave single doses, so it describes pharmacokinetics, pharmacodynamics, and short-term tolerability without information on repeated dosing or on patients with hyperinsulinism.
- Only the abstract and company releases are openly available; the full text, with eligibility, disposition, baseline characteristics, and adverse event tables, is closed access, and no registry identifier was found. The reported number of healthy volunteers differs across documents (29 in the publication; 22 across two phase 1 studies in a later publication).